OTCMKTS:USRM U.S. Stem Cell (USRM) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 04/25/2025 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsBuy This Stock About U.S. Stem Cell Stock (OTCMKTS:USRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get U.S. Stem Cell alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume23,621 shsAverage Volume153,162 shsMarket Capitalization$66,150.70P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewU.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.Read More… Receive USRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address USRM Stock News HeadlinesNew approach targets cell surface protein to treat leukemia and solid tumorsApril 24 at 4:57 AM | msn.comNeural stem cells outside the brain: Discovery opens new paths for regenerative medicineApril 10, 2025 | msn.comTrump’s Secret Social Security Plan?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)World’s first human trial of sperm stem cell therapy aims to reverse male infertilityApril 7, 2025 | msn.comDrug-delivering aptamers target leukemia stem cells for a one-two knockout punchApril 3, 2025 | msn.comScientists create universal vascular graft with stem cells to improve surgery for cardiovascular diseaseMarch 10, 2025 | msn.comFLIpping the switch: DNA regulator activates blood stem cells for improved transplantation successMarch 10, 2025 | msn.comStem cell transplant clears clinical safety hurdle for treatment of wet age-related macular degenerationFebruary 27, 2025 | msn.comSee More Headlines USRM Stock Analysis - Frequently Asked Questions How have USRM shares performed this year? U.S. Stem Cell's stock was trading at $0.0001 at the beginning of the year. Since then, USRM shares have increased by 0.0% and is now trading at $0.0001. View the best growth stocks for 2025 here. How were U.S. Stem Cell's earnings last quarter? U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The business had revenue of $1.30 million for the quarter. How do I buy shares of U.S. Stem Cell? Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of U.S. Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some other companies that U.S. Stem Cell investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Auxly Cannabis Group (CBWTF), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX). Company Calendar Last Earnings8/07/2019Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CIK1388319 Webwww.us-stemcell.com Phone(954) 835-1500Fax954-845-9976Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$80,000.00 Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares661,507,000Free Float550,903,000Market Cap$66,150.70 OptionableNot Optionable Beta-1.33 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:USRM) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding U.S. Stem Cell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share U.S. Stem Cell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.